Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.

National Jewish Health8 enrolled

Overview

This is an observational study of people with severe cystic fibrosis that are eligible for Vertex's triple combination therapy through its expanded access. Pulmonary health, intestinal health, and the overall health of individuals will be tracked for a year to see how effective triple combination therapy is in these people with severe cystic fibrosis disease.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cystic Fibrosis

Interventions

Triple combination therapyDRUG

Triple combination is compromised of the drugs ivacaftor, tezacaftor and Vertex's next generation modulator.

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Confirmed diagnosis of Cystic Fibrosis * Ability to reproducibly perform spirometry (according to ATS criteria) * Physician decision to treat with TCT through the EAP program * Ability to understand and sign a written informed consent or assent and comply with the requirements of the study Exclusion Criteria: * History of hypersensitivity to VX 445, VX 659, tezacaftor and/or ivacaftor * Any acute lower respiratory symptoms treated with oral, inhaled or IV antibiotics or systemic corticosteroids within the 2 weeks prior to Visit 1. * Major or traumatic surgery within 12 weeks prior to Visit 1. * Initiation of any new chronic therapy (e.g., ibuprofen, Pulmozyme®, hypertonic saline, azithromycin, TOBI®, Cayston®) within 4 weeks prior to Visit 1. * Use of an investigational agent within 28 days prior to Visit 1. * History of lung or liver transplantation or listing for organ transplantation.

Locations (1)

National Jewish Health

Denver, Colorado, United States

Outcomes

Primary Outcomes

pulmonary function

FEV1 values.

Time frame: For a year post initiation of therapy.

Secondary Outcomes

CFQ-R score

cystic fibrosis questionnaire - revised has sections to measure pulmonary health and gastrointestinal health.

Time frame: For a year following the initiation of triple combination therapy.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.